Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS 93 5-Year Yield-on-Cost % is 1.70 as of Jul. 23, 2026, which is 400% above its 10-year median of 0.34. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr182.08 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 277 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks worse than 58.48% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:RAYBs'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.09 Med: 0.34 Max: 1.72
Current: 1.7
During the past 13 years, RaySearch Laboratories AB's highest Yield on Cost was 1.72. The lowest was 0.09. And the median was 0.34.
CHIX:RAYBs's 5-Year Yield-on-Cost % is ranked worse than 58.48% of 277
companies
in the Healthcare Providers & Services industry
Industry Median: 2.93
vs CHIX:RAYBs: 1.70
RaySearch Laboratories AB (CHIX:RAYBs) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
RaySearch Laboratories AB 5-Year Yield-on-Cost % Related Terms
CHIX:RAYBS vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's 5-Year Yield-on-Cost % falls into.
RaySearch Laboratories AB 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
RaySearch Laboratories AB (CHIX:RAYBS) has a 5-Year Yield-on-Cost % of 1.70 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on RaySearch Laboratories AB and its competitors. This is 400% above median its historical median of 0.34. Over the past decade, RaySearch Laboratories AB's 5-Year Yield-on-Cost % has ranged from 0.09 to 1.72. According to the industry distribution chart, RaySearch Laboratories AB ranks #162 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 58.5%.
Is RaySearch Laboratories AB's 5-Year Yield-on-Cost % too high?
RaySearch Laboratories AB's current 5-Year Yield-on-Cost % of 1.70 is 400% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 1.72. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.93. RaySearch Laboratories AB's value of 1.70 is 42% below this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #162 out of 277 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #162 out of 277 companies for 5-Year Yield-on-Cost %. This places RaySearch Laboratories AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.93. RaySearch Laboratories AB's value of 1.70 is 42% below this benchmark. Historically, RaySearch Laboratories AB's own 5-Year Yield-on-Cost % has ranged from 0.09 to 1.72 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 2.93, RaySearch Laboratories AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current 5-Year Yield-on-Cost % of 1.70 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current 5-Year Yield-on-Cost % is 1.70, which is 400% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr182.08, compared to a current price of kr234.70 — trading 28.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.70, which is 400% above median its 10-year median of 0.34 and 42% below the Healthcare Providers & Services industry median of 2.93. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current 5-Year Yield-on-Cost % is 1.70 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 28.9% above its estimated GF Value™ of kr182.08.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for CHIX:RAYBS:
5-Year Yield-on-Cost %: 1.70 (400% above median its 10-year median of 0.34)
GF Value™: kr182.08 vs. price of kr234.70 (28.9% above fair value)
Industry Position: 42% below the Healthcare Providers & Services median (#162 of 277)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
